248 related articles for article (PubMed ID: 18846037)
1. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models.
Naguib M; Diaz P; Xu JJ; Astruc-Diaz F; Craig S; Vivas-Mejia P; Brown DL
Br J Pharmacol; 2008 Dec; 155(7):1104-16. PubMed ID: 18846037
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats.
Wu J; Hocevar M; Bie B; Foss JF; Naguib M
J Pain; 2019 May; 20(5):501-514. PubMed ID: 30414958
[TBL] [Abstract][Full Text] [Related]
4. Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system.
Naguib M; Xu JJ; Diaz P; Brown DL; Cogdell D; Bie B; Hu J; Craig S; Hittelman WN
Anesth Analg; 2012 May; 114(5):1104-20. PubMed ID: 22392969
[TBL] [Abstract][Full Text] [Related]
5. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
Deng L; Cornett BL; Mackie K; Hohmann AG
Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
[TBL] [Abstract][Full Text] [Related]
7. Activation of cannabinoid receptor 2 attenuates mechanical allodynia and neuroinflammatory responses in a chronic post-ischemic pain model of complex regional pain syndrome type I in rats.
Xu J; Tang Y; Xie M; Bie B; Wu J; Yang H; Foss JF; Yang B; Rosenquist RW; Naguib M
Eur J Neurosci; 2016 Dec; 44(12):3046-3055. PubMed ID: 27717112
[TBL] [Abstract][Full Text] [Related]
8. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat.
Scott DA; Wright CE; Angus JA
Pain; 2004 May; 109(1-2):124-31. PubMed ID: 15082134
[TBL] [Abstract][Full Text] [Related]
9. Spinal gene expression profiling and pathways analysis of a CB2 agonist (MDA7)-targeted prevention of paclitaxel-induced neuropathy.
Xu JJ; Diaz P; Bie B; Astruc-Diaz F; Wu J; Yang H; Brown DL; Naguib M
Neuroscience; 2014 Feb; 260():185-94. PubMed ID: 24361916
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
12. Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain.
Curto-Reyes V; Llames S; Hidalgo A; Menéndez L; Baamonde A
Br J Pharmacol; 2010 Jun; 160(3):561-73. PubMed ID: 20233215
[TBL] [Abstract][Full Text] [Related]
13. Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers.
Bingham B; Jones PG; Uveges AJ; Kotnis S; Lu P; Smith VA; Sun SC; Resnick L; Chlenov M; He Y; Strassle BW; Cummons TA; Piesla MJ; Harrison JE; Whiteside GT; Kennedy JD
Br J Pharmacol; 2007 Aug; 151(7):1061-70. PubMed ID: 17549048
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of 2-amido-3-carboxamide thiophene CB₂ receptor agonists for pain management.
Nelson DW; Frost JM; Tietje KR; Florjancic AS; Ryther K; Carroll WA; Dart MJ; Daza AV; Hooker BA; Grayson GK; Fan Y; Garrison TR; El-Kouhen OF; Yao B; Pai M; Chandran P; Zhu C; Hsieh GC; Meyer MD
Bioorg Med Chem Lett; 2012 Apr; 22(7):2604-8. PubMed ID: 22370265
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists.
van der Stelt M; Cals J; Broeders-Josten S; Cottney J; van der Doelen AA; Hermkens M; de Kimpe V; King A; Klomp J; Oosterom J; Pols-de Rooij I; de Roos J; van Tilborg M; Boyce S; Baker J
J Med Chem; 2011 Oct; 54(20):7350-62. PubMed ID: 21923175
[TBL] [Abstract][Full Text] [Related]
17. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery.
Rahn EJ; Deng L; Thakur GA; Vemuri K; Zvonok AM; Lai YY; Makriyannis A; Hohmann AG
Mol Pain; 2014 Apr; 10():27. PubMed ID: 24742127
[TBL] [Abstract][Full Text] [Related]
19. The cannabinoid CB₂ receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain.
Klauke AL; Racz I; Pradier B; Markert A; Zimmer AM; Gertsch J; Zimmer A
Eur Neuropsychopharmacol; 2014 Apr; 24(4):608-20. PubMed ID: 24210682
[TBL] [Abstract][Full Text] [Related]
20. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.
Sagar DR; Jhaveri MD; Richardson D; Gray RA; de Lago E; Fernández-Ruiz J; Barrett DA; Kendall DA; Chapman V
Eur J Neurosci; 2010 Apr; 31(8):1414-22. PubMed ID: 20384778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
